Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Streamlined Method for Telomere Length Measurement Opens New Cancer Diagnostic Opportunities

By LabMedica International staff writers
Posted on 01 Sep 2020
In a novel approach to cancer diagnosis, researchers have developed a high-throughput digital real-time PCR method for rapidly measuring the absolute lengths and quantities of individual telomere molecules.

Genomic studies have shown that telomere length is a promising biomarker for age-associated diseases and cancer. More...
A telomere is a region of repetitive nucleotide sequences at each end of a chromosome, which protects the end of the chromosome from deterioration or from fusion with neighboring chromosomes. In humans, average telomere length declines from about 11 kilobases at birth to fewer than four kilobases in old age, with the average rate of decline being greater in men than in women. Cancer cells have developed mechanisms to modify and maintain the length of their telomeres, as a means to allow them to grow continually. Currently, clinical analysis of telomeres is rarely carried out due to the lack of a simple and rapid measurement technique.

To streamline telomere analysis, investigators at the National University of Singapore and their collaborators developed the “single telomere absolute-length rapid assay” (STAR), a novel high-throughput digital real-time PCR approach for rapidly measuring the absolute lengths and quantities of individual telomere molecules.

The STAR method, which is based on DNA microarray technology, can measure the absolute telomere length of individual telomeres in less than three hours for up to 48 samples from low amounts (less than one nanogram) of extracted DNA. Moreover, the STAR assay has a wide dynamic range of measurement, as it is capable of measuring telomere lengths from 0.2 to 320 kilobases.

The investigators used the STAR approach to characterize human cancer cell lines and human clinical samples. They reported detecting the telomere maintenance mechanism of each sample accurately based on telomere length distributions. This enabled them to diagnose patients with cancers activated by the Alternative Lengthening of Telomere (ALT) pathway, such as certain sarcomas and gliomas. In particular, the STAR assay was effective in diagnosing the ALT status in pediatric neuroblastoma, which can serve as a useful prognosis indicator for this cancer.

"Our innovation could greatly enhance the speed of diagnosis and simultaneously provide critical telomere information for age-related diseases and cancers. Such a clinically reliable tool that is able to provide accurate telomere profiling will allow for precision therapy and targeted treatments for patients," said senior author Dr. Cheow Lih Feng, assistant professor of biomedical engineering. "The combination of rapid workflow, scalability, and single-molecule resolution makes our system unique in enabling the use of telomere length distribution as a biomarker in disease and population-wide studies. It will be particularly useful for diagnosing telomere maintenance mechanisms within clinical time scales, to determine personalized, therapeutic, or preventive strategies for patients."

The STAR assay was described in the August 21, 2020, online edition of the journal Science Advances.

Related Links:
National University of Singapore


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.